Introduction: Hyperthyroidism, an endocrine disorder characterized by an overactive thyroid gland, leads to increased levels of circulating thyroid hormones (T3 and T4), affecting numerous metabolic and physiological processes throughout the body. Objective: To find the changes in liver function, fluctuations in blood glucose, insulinsecretion and gender differences in patients with hyperthyroidism aftertreatment with propranolol hydrochloride tablets coalition withmethimazole tablets.Methodology: This comparative observational study was conducted and total of 165 patients diagnosed with hyperthyroidism were selected for this study. Patients with confirmed diagnosis of hyperthyroidism and had not previously received beta-blocker or antithyroid medication were included in the study. Patients with existing liver disease, diabetes, or other endocrine disorders that could impact metabolic outcomes were excluded. Results: Data were collected from 165 patients. Liver enzymes, specifically AST, ALT, and ALP, showed notable reductions of 25%, 30%, and 15%, respectively, with male patients experiencing greater enzyme decreases compared to females. Blood glucose levels also improved, with a 10% reduction in fasting blood glucose and a 15% decrease in OGTT levels, where females demonstrated a more pronounced improvement in glucose tolerance. The pre-treatment insulin sensitivity parameters reveal higher insulin resistance and fasting insulin levels in male hyperthyroid patients compared to females. Specifically, the mean HOMA-IR for males was 5.0 ± 1.2, while females had a slightly lower mean of 4.4 ± 1.0, indicating comparatively greater insulin sensitivity in females. Conclusion: It is concluded that combined propranolol and methimazole therapy is effective in managing hyperthyroidism by significantly improving liver function, blood glucose regulation, and insulin sensitivity.